FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_					
\sim	MR	ΛD	00	\cap	/ N I

п		
ı	OMB Number:	3235-0287
	Estimated average burden	
ı	hours per response.	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Rawcliffe Adrian (Last) (First) (Middle) C/O ADAPTIMMUNE THERAPEUTICS PLC,			2. Issuer Name and Ticker or Trading Symbol Adaptimmune Therapeutics PLC [ADAP]	Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
			3. Date of Earliest Transaction (Month/Day/Year) 06/27/2023	X	Officer (give title below) Chief Executive Officer (Size of Executive Offi	Other (specify below)		
60 JUBILEE AVENUE, MILTON PARK (Street) ABINGDON X0 OX14 4RX			4. If Amendment, Date of Original Filed (Month/Day/Year)	Individual or Joint/Group Filing (Check Applicable Lin X Form filed by One Reporting Person Form filed by More than One Reporting Person Form filed Person Form				
(City)	(State)	(Zip)	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contra affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.	ct, instruct	ion or written plan that is intended	to satisfy the		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Oate, Transaction Code (Instr.		4. Securities Ad Disposed Of (D			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)	
American Depositary Shares representing Ordinary Shares ⁽¹⁾	06/27/2023		S		2,333	D	\$0.92(2)	3,519(3)	D		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative	Conversion		3A. Deemed Execution Date,	Transaction		Derivative		Expiration Date		7. Title and Amount of Securities Underlying		Derivative	9. Number of derivative	10. Ownership		۱
Security (Instr. 3)	or Exercise Price of	(Month/Day/Year)	if any (Month/Day/Year)	8)		Acquired (A)		` '		Derivative Security (Instr. 3 and 4)		Security (Instr. 5)	Securities Beneficially	Form: Direct (D)	Beneficial Ownership	١
	Derivative Security			or Disposed of (D) (Instr. 3, 4 and 5)						Owned Following Reported Transaction(s)	or Indirect (I) (Instr. 4)					
								D-4-	F		Amount		(Instr. 4)			
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Number of Shares					

Explanation of Responses:

- 1. Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on June 27, 2019 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.
- 2. The price reported in Column 4 is the sale price per ADS.
- 3. The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 155,103 ADSs and RSU-style options and other options covering an aggregate of 27,496,302 ordinary shares of the Issuer.

<u>/s/ Adrian George Rawcliffe</u> 06/27/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.